No Impact of Long-Term Fingolimod Treatment on Fecal Secretory Immunoglobulin A Levels in Patients With Multiple Sclerosis

BACKGROUND: Fingolimod (FTY) is a sphingosine 1 phosphate (S1P) agonist with significant effects on immune cell distribution used as an effective disease modifying therapy in multiple sclerosis (MS) patients. Animal studies have demonstrated that a dysregulation of egress of murine secretory Immungl...

Descripción completa

Detalles Bibliográficos
Autores principales: Inojosa, Hernan, Eisele, Judith, Proschmann, Undine, Zeissig, Sebastian, Akgün, Katja, Ziemssen, Tjalf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Cell and Developmental Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7546410/
https://www.ncbi.nlm.nih.gov/pubmed/33102475
http://dx.doi.org/10.3389/fcell.2020.567659

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7546410/
https://www.ncbi.nlm.nih.gov/pubmed/33102475
http://dx.doi.org/10.3389/fcell.2020.567659

Ejemplares similares